Search Results

Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced the results of the Combined Shareholders Meeting which took place on May 22, 2024.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2023.

GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

GENFIT, a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, announced the publication of its 2024 Extra-Financial Performance Report.